Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March
Exelixis, Inc. (Nasdaq: EXEL) announced that CEO Michael M. Morrissey, Ph.D., will take part in several virtual investor conferences in March 2021. Key presentations include:
- Cowen 41st Annual Healthcare Conference on March 1 at 2:40 PM EST.
- Barclays Global Healthcare Conference on March 9 at 11:30 AM EST.
- Oppenheimer 31st Annual Healthcare Conference on March 16 at 11:20 AM EDT.
Investors can access the webcasts on the Exelixis website, with replays available for 14 days.
- None.
- None.
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in fireside chats at the following virtual investor conferences in March:
- Cowen 41st Annual Healthcare Conference: Exelixis is scheduled to present at 2:40 PM EST / 11:40 AM PST on Monday, March 1, 2021.
- Barclays Global Healthcare Conference 2021: Exelixis is scheduled to present at 11:30 AM EST / 8:30 AM PST on Tuesday, March 9, 2021.
- Oppenheimer 31st Annual Healthcare Conference: Exelixis is scheduled to present at 11:20 AM EDT / 8:20 AM PDT on Tuesday, March 16, 2021.
To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune’s 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225006156/en/
FAQ
What are the dates of Exelixis' upcoming virtual conferences in March 2021?
What time will Exelixis present at the Cowen 41st Annual Healthcare Conference?
Where can I access the webcasts for Exelixis' investor presentations?
How long will replays of Exelixis' presentations be available?
Who is the CEO of Exelixis participating in the investor conferences?
